Bionomics (BNOEF) Stock Price, News & Analysis

Company Overview

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Key Stats

• Today's Range: $0.0034 to $0.0034
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.06
• Volume: 22,900 shs
• Average Volume: 140,299 shs
• Market Capitalization: $4.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BNOEF Stock Analysis - Frequently Asked Questions

How have BNOEF shares performed this year?

Bionomics' stock was trading at $0.0034 on January 1st, 2025. Since then, BNOEF shares have increased by 0.0% and is now trading at $0.0034.
View the best growth stocks for 2025 here.

How do I buy shares of Bionomics?

Shares of BNOEF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 6/27/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Noncommercial research organizations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BNOEF
• CIK: 1191070
• Web: www.bionomics.com.au
• Phone: (188) 150-7400
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,309,557,000
• Free Float: N/A
• Market Cap: $4.45 million
• Optionable: Not Optionable
• Beta: 1.86